Glucose– tag –
-
FDA Warns: Smartwatches Lack Medical-Grade Accuracy for Non-Invasive Blood Glucose Monitoring in 2026
[Unnamed Health Publication] USA Overview As of 2026, peer-reviewed research on non-invasive blood glucose monitoring via consumer wearables remains limited. The FDA and Johns Hopkins University explicitly state no wrist-worn device exis... -
Non-Invasive Blood Sugar Monitoring Faces Accuracy and Reliability Hurdles; True Non-Invasive Devices Remain Undeveloped
Health.com USA Overview While non-invasive blood sugar meters hold promise for finger-prick-free glucose checks, most currently available devices fail to meet the expected medical-grade accuracy and reliability for daily tracking. Many p... -
Dorsey & Whitney Trust CO LLC Sells Abbott Laboratories Shares Amidst Focus on Libre Duo CE Mark Approval
MarketBeat USA Overview Dorsey & Whitney Trust CO LLC has reduced its holdings in Abbott Laboratories shares. Despite this divestment, Abbott is gaining significant attention for its recent CE Mark approval of Libre Duo, an innovativ... -
Erste Group Bank Adjusts Abbott’s FY2027 Earnings Outlook Downward, Highlights Libre Duo CE Mark as Key Growth Driver
MarketBeat USA Overview Erste Group Bank has slightly lowered its fiscal year 2027 earnings outlook for Abbott Laboratories, yet emphasizes Abbott's recent CE Mark approval for its innovative Libre Duo dual glucose-ketone sensing technol... -
Cambridge University & GlitterinTech Develop $10 Spectrometer Chip Delivering Lab-Grade Chemical Analysis for Non-Invasive Wearable Biomarker Monitoring
Rasayanika UK Overview Researchers from Cambridge University and GlitterinTech have developed a compact spectrometer chip costing approximately $10, capable of lab-grade chemical analysis. This centimeter-scale chip holds the potential f... -
Diabetes Devices Dominate FDA MAUDE Reports 2020-2025 with Over 50% of Adverse Events, Dexcom Largest Single Reporter
Global MedTech Expert | 10× MedTech Global Access Unknown Overview An analysis of 14.4 million FDA MAUDE adverse event reports from 2020 to 2025 reveals that diabetes-related devices account for over half of all reported events. Continuo... -
Supply Chain Integrity Under Fire: Pharmsource Denies Knowledge of Stolen, Recalled Dexcom G7 Sensors
Investing.com 南アフリカ Overview Pharmaceutical wholesaler Pharmsource LLC denies knowing that Dexcom G7 continuous glucose monitoring (CGM) sensors it acquired were stolen post-disposal and resold, despite being originally slated for d... -
Goodman Advisory Group Invests $1.29 Million in DexCom Amidst Strong Q1 Performance, Revenue Soars 15% to $1.19 Billion
MarketBeat USA Overview Goodman Advisory Group has made a strategic investment of $1.29 million in DexCom, a leading continuous glucose monitoring (CGM) company, following DexCom's strong first-quarter earnings report. The company achiev... -
Senseonics Presents Eversense 365 Real-World Data at ADA Scientific Sessions, Highlights 180-Day Wear for Unmet CGM Needs
Peninsula Fly Fishers USA Overview Senseonics Holdings presented real-world evidence for its Eversense 365 implantable continuous glucose monitoring (CGM) system during the American Diabetes Association (ADA)'s 86th Scientific Sessions. ... -
i-SENS’s CareSens Air CGM Secures Belgian Reimbursement, Paving the Way for Expanded European Market Penetration
i-SENS (アジア経済新聞経由) South Korea, ベルギー Overview South Korean medical device firm i-SENS has achieved a critical milestone with its "CareSens Air" continuous glucose monitoring (CGM) device, securing public insurance reimbursem...
